BACKGROUNDParacoccidioidomycosis (PCM) is one of the most important systemic mycoses in
Latin America and the leading fungal cause of mortality in non-immunosuppressed
individuals in Brazil. However, HIV/PCM co-infection can increase the clinical
severity in these co-infected patients. This co-infection is rarely reported in
the literature mainly because of the different epidemiological profiles of these
infections. Furthermore, PCM is a neglected and non-notifiable disease, which may
underestimate the real importance of this disease. The advent of molecular studies
on the species of the genus Paracoccidioides has expanded the
knowledge regarding the severity and the clinical spectrum in PCM. In this
context, the development of studies to describe the association of the
Paracoccidioides phylogenetic cryptic species in vulnerable
populations, such as HIV-infected patients, appears relevant.OBJECTIVETo describe the clinical, epidemiological, therapeutic and prognostic aspects in
HIV/PCM co-infected patients, along with the molecular identification of the
Paracoccidioides species involved in these cases.METHODSThe investigators performed a molecular and clinical retrospective study involving
HIV/PCM co-infected patients, from a reference centre for PCM care in the endemic
area of Rio de Janeiro, Brazil, from 1998 to 2015. Molecular identification of the
fungal strains was done by amplification of partial sequences of
arf and gp43 genes.FINDINGSOf 89 patients diagnosed with PCM by fungal isolation in the culture, a viable
isolate was recovered for molecular analysis from 44 patients. Of these 44
patients, 28 (63.6%) had their serum samples submitted for enzyme immunoassay
tests for screening of HIV antibodies, and 5 (17.9%) had a positive result. All
cases were considered severe, with a variable clinical presentation, including
mixed, acute/subacute clinical forms and a high rate of complications, requiring
combination therapy. Paracoccidioides brasiliensis S1 was the
species identified in all cases.CONCLUSIONSHIV/PCM co-infection can change the natural history of this fungal disease. The
authors reinforce the need to include HIV screening diagnostic tests routinely for
patients with PCM.